행사/교육
Exploratory Clinical Development World Europe 2013
- 등록일2013-02-19
- 조회수4441
- 구분 국외
- 행사교육분류 행사
-
주관기관
Health Network Communications Ltd
-
행사장소
Jumeirah Carlton Tower Hotel - London
-
행사기간
2013-06-04 ~ 2013-06-06
- 원문링크
- 첨부파일
brochure.pdf
Exploratory Clinical Development World Europe 2013
Show overview
Now in its 7th year, Exploratory Clinical Development World Europe has established itself as the largest & most influential event for pharma & biotech representatives working within exploratory development & early phase clinical trials.
Avoid the futility and expense of carrying ineffective novel agents into full scale clinical development by learning current methods to assess safety and efficacy.
conference programme
Biologics Focus Day
Conference
8.30am Registration and Refreshments
9.15am Opening Remarks
9.30am Preparing for the translation of biologics into man: Key questions to ask prior to clinical testing
› Dr Mark Penney, Principal Clinical Pharmacokineticist, MedImmune
Preparing for the translation of biologics into man: Key questions to ask prior to clinical testing
10.15am Bi-specific TCR anti-CD3 fusions for cancer immunotherapy
› Dr Namir Hassan, Director of Translational Research, Immunocore
Bi-specific TCR anti-CD3 fusions for cancer immunotherapy
11am Morning Refreshments
11.30am Preclinical safety evaluations for biologics
› Dr Simon Henderson, Senior Toxicologist Biologics Safety Assessment, MedImmune
Preclinical safety evaluations for biologics
12.15pm Establishing dosing regimens for biologics in first-in-man studies
› Dr Penelope Ward, Head of Clinical Strategy, Immunology TA, New Medicines, UCB
Establishing dosing regimens for biologics in first-in-man studies
1pm Networking Lunch
2pm Safety and risk management for biologics in the clinic
› Dr Heather Hinton, Head Immunosafety, Early & Investigative Safety, Roche
Safety and risk management for biologics in the clinic
2.45pm Regulatory considerations for early clinical trials in biologics
3.30pm Utilization of biomarkers in non-clinical development to guide early phase clinical development: Case studies with Nanobodies
› Dr Josefin-Beate Holz, Chief Medical Officer, Ablynx
Utilization of biomarkers in non-clinical development to guide early phase clinical development: Case studies with Nanobodies
4.15pm Summary and closing remarks from the chair
4.30pm End of Day
........(계속)
☞ 자세한 내용은 내용바로가기를 이용하시기 바랍니다.